The Journal of Allergy and Clinical Immunology
Volume 117, Issue 4 , Pages 767-773 , April 2006

Bronchial challenges in athletes applying to inhale a β2-agonist at the 2004 Summer Olympics

  • Sandra D. Anderson, PhD, DSc

      Affiliations

    • From the Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown
    • Corresponding Author InformationReprint requests: Sandra D. Anderson, PhD, DSc, Department of Respiratory Medicine, E 11, Royal Prince Alfred Hospital, Camperdown NSW 2050, Australia.
    • ,
  • Malcolm Sue-Chu, MB ChB, PhD

      Affiliations

    • Department of Lung Medicine, St Olavs Hospital, Trondheim University Hospital, Trondheim
    • ,
  • Clare P. Perry, BSc, Dip Ed

      Affiliations

    • From the Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown
    • ,
  • Christina Gratziou, MD, PhD

      Affiliations

    • Pulmonary and Critical Care Department, Asthma and Allergy Center, Medical School, University of Athens
    • ,
  • Pascale Kippelen, PhD

      Affiliations

    • From the Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown
    • ,
  • Don C. McKenzie, MD, PhD

      Affiliations

    • Division of Sports Medicine, The University of British Columbia, Vancouver
    • ,
  • Ken C. Beck, PhD

      Affiliations

    • Guidant Corp, St Paul
    • ,
  • Ken D. Fitch, MBBS, MD

      Affiliations

    • School of Human Movement and Exercise Science, University of Western Australia, Nedlands

Received 22 July 2005 ,Revised 15 December 2005 ,Accepted 19 December 2005.

  • Image Result

    The total number of competitors and applications received for the Summer Games in Athens, the bronchial provocation tests performed, and the numbers approved and rejected. HS, Hypertonic (4.5%) saline

    The total number of competitors and applications received for the Summer Games in Athens, the bronchial provocation tests performed, and the numbers approved and rejected. HS, Hypertonic (4.5%) saline; EIA, exercise-induced asthma.

  • Image Result
    Individual values for the decrease in FEV1 after exercise and EVH in athletes using ICSs and those not using ICSs. The majority of responses documented were severe enough to suggest that the athletes

    Individual values for the decrease in FEV1 after exercise and EVH in athletes using ICSs and those not using ICSs. The majority of responses documented were severe enough to suggest that the athletes would benefit from better treatment of their asthma.

  • Image Result
    Individual values for the dose (PD20) or concentration (PC20) of methacholine required to provoke a 20% decrease in FEV1. Note that the majority of subjects being treated with ICSs had values within t

    Individual values for the dose (PD20) or concentration (PC20) of methacholine required to provoke a 20% decrease in FEV1. Note that the majority of subjects being treated with ICSs had values within the same range as those not being treated with ICSs.

 Supported by the International Olympic Committee Medical Commission.Disclosure of potential conflict of interest: S. Anderson has consulting arrangements with Pharmaxis Ltd; owns stock in Pharmaxis Ltd; is inventor of a bronchial hyperresponsiveness test, patent owned by her employer, Central Sydney Area Health Service and licensed to Pharmaxis; and has received grant support from National Health and Medical Research Council of Australia. No Conflict of Interest disclosure statement was received from C. Gratziou. The rest of the authors have declared they have no conflict of interest.

PII: S0091-6749(06)00177-1

doi: 10.1016/j.jaci.2005.12.1355

The Journal of Allergy and Clinical Immunology
Volume 117, Issue 4 , Pages 767-773 , April 2006

Article Tools

* Image Usage & Resolution